

08/958570

Search result

Refine Search

Search Results -

Terms	Documents
L5 and (thymidine near kinase\$ or cytosine near deaminase)	22

Database:
 US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins
Search:

<input type="text" value="L6"/>	<input type="button" value="Refine Search"/>
<input type="button" value="Recall Text"/> <input type="button" value="Clear"/> <input type="button" value="Interrupt"/>	

Search History

DATE: Tuesday, August 24, 2004 [Printable Copy](#) [Create Case](#)

Set Name	Query	Hit Count	Set Name result set
<u>side by side</u>			
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L6	L5 and (thymidine near kinase\$ or cytosine near deaminase)	22	L6
L5	L4 and suicide	22	L5
L4	L3 and (E1a and E1b)	40	L4
L3	L2 and (tumor near suppressor\$ or p53 or p21 or WT1 or p16 or mitosin or Rb)	47	L3
L2	L1 and pIX near10 (delet\$ or absent\$ or lack\$)	74	L2
L1	adenovir\$ near5 vector\$	17282	L1

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)

Search Results - Record(s) 1 through 47 of 47 returned.

1. 20040121976. 26 Sep 03. 24 Jun 04. Anti-inflammatory vectors. Rooke, Ronald. 514/44; 435/456 A61K048/00 C12N015/861.

2. 20040091456. 26 Nov 02. 13 May 04. Novel recombinant adenovirus vector with relieved side effects. Nakai, Michio, et al. 424/93.2; 435/456 A61K048/00 C12N015/861.

3. 20040087027. 23 Jun 03. 06 May 04. Recombinant adenoviral vector and methods of use. Gregory, Richard J., et al. 435/456; 435/235.1 C12N007/00 C12N015/861.

4. 20040063203. 28 Oct 03. 01 Apr 04. Non-adenoviral gene product-based complementing cells for adenoviral vectors. Brough, Douglas E., et al. 435/369; 435/456 C12N005/08 C12N015/861.

5. 20040038404. 19 May 03. 26 Feb 04. Recombinant adenoviral vector and methods of use. Gregory, Richard J., et al. 435/456; 435/235.1 435/320.1 C12N015/861 C12N007/00.

6. 20030228280. 31 Jan 03. 11 Dec 03. System for production of helper dependent adenovirus vectors based on use of endonucleases. Graham, Frank L., et al. 424/93.2; 435/235.1 435/325 435/457 A61K048/00 C12N007/00 C12N015/861.

7. 20030219410. 31 Jan 03. 27 Nov 03. Adenoviral vectors for modulating the cellular activities associated to PODs. Calatrava, Manuel Rosa. 424/93.2; 435/456 A61K048/00 C12N015/861.

8. 20030211598. 03 Jun 03. 13 Nov 03. Compositions and methods for therapeutic use. Engler, Heidrun, et al. 435/320.1; 424/93.2 435/456 A61K048/00 C12N015/861.

9. 20030185801. 15 Nov 01. 02 Oct 03. Complementing cell lines. Vogels, Ronald, et al. 424/93.2; 435/235.1 435/325 435/456 A61K048/00 C12N007/00 C12N015/861 C12N005/06 A01N063/00 C12N007/01 C12N005/00 C12N005/02 C12N015/86.

10. 20030171336. 04 Jun 02. 11 Sep 03. Complementing cell lines. Vogels, Ronald, et al. 514/100; 435/235.1 435/320.1 435/325 514/44 A61K031/70 A01N043/04 A61K031/665 A01N057/00 C12N007/00 C12N007/01 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74 C12N005/00 C12N005/02.

11. 20030119192. 15 Oct 02. 26 Jun 03. Complementing cell lines. Vogels, Ronald, et al. 435/456; 435/235.1 435/366 C12N007/00 C12N005/08 C12N015/861.

12. 20030108524. 18 Oct 02. 12 Jun 03. Vectors for expressing multiple transgenes. Diagana, Melissa, et al. 424/93.2; 435/320.1 435/456 435/6 800/14 A61K048/00 C12Q001/68 A01K067/027 C12N015/861.

13. 20030108521. 30 May 02. 12 Jun 03. Adenovirus protein IX, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization. Calatrava, Manuel Rosa. 424/93.2; 424/186.1 435/235.1 435/320.1 435/325 435/456 435/69.3 530/350 536/23.72 A61K048/00 A61K039/12 C07H021/04 C12P021/02 C12N005/06 C07K014/075 C12N007/00 C12N015/861.

14. 20030091534. 18 May 01. 15 May 03. Adenoviral vectors having a protein IX deletion. Gregory, Richard, et al. 424/93.2; 435/235.1 435/320.1 435/456 A61K048/00 C12N007/00 C12N015/861.

15. 20030087438. 02 Nov 01. 08 May 03. E1-revertant-free adenoviral composition. Brough, Douglas E., et al. 435/456; 435/235.1 435/239 A61K048/00 C12N015/861 C12N007/02 C12N007/00.

16. 20030086904. 17 May 02. 08 May 03. Therapeutic regimen for treating cancer. Rasmussen, Henrik S., et al. 424/93.2; 435/235.1 435/456 A61K048/00 C12N007/00 C12N015/861.

17. 20030086903. 02 Nov 01. 08 May 03. Therapeutic regimen for treating cancer. Rasmussen, Henrik S., et al. 424/93.1; A01N063/00.

18. 20030054553. 23 Jul 01. 20 Mar 03. Adenovector complementing cells. Brough, Douglas E., et al. 435/456; 435/235.1 435/320.1 435/366 C12N015/861 C12N007/00 C12N005/08.

19. 20030053989. 14 Sep 01. 20 Mar 03. Method of modulating neovascularization. Kovesdi, Imre. 424/93.2; 435/456 514/44 A61K048/00 C12N015/861.

20. 20030040100. 23 Jul 01. 27 Feb 03. Cell for the propagation of adenoviral vectors. Brough, Douglas E., et al. 435/235.1; 435/239 435/325 536/23.72 536/24.1 C12N007/02 C12N005/02 C07H021/04 C12N005/00 C12N007/01 C12N007/00.

21. 20030017595. 23 Jul 01. 23 Jan 03. Non-adenoviral gene product-based complementing cells for adenoviral vectors. Brough, Douglas E., et al. 435/456; 435/235.1 435/320.1 435/366 C12N015/861 C12N007/01 C12N005/08.

22. 20020152486. 09 May 01. 17 Oct 02. Vascular specific regulatory elements contained in the desmin 5' flanking region. Paulin, Denise, et al. 800/14; 435/183 435/320.1 435/325 435/69.1 536/23.2 A01K067/027 C07H021/04 C12N009/00 C12P021/02 C12N005/06.

23. 20020137212. 18 May 01. 26 Sep 02. Adenoviral vectors having a protein IX deletion. Gregory, Richard J., et al. 435/456; 435/235.1 435/320.1 C12N015/861 C12N007/01.

24. 20020136708. 19 Jun 01. 26 Sep 02. System for production of helper dependent adenovirus vectors based on use of endonucleases. Graham, Frank L., et al. 424/93.21; 435/235.1 435/457 536/23.72 A61K048/00 C07H021/04 C12N007/00 C12N015/861.

25. 20020111502. 22 Jan 02. 15 Aug 02. Compositions and methods for enhancing delivery of therapeutic agents to cells. Engler, Heidrun, et al. 552/550; 536/53 A61K048/00 A61K031/7008 C07J041/00 C08B037/00 A61K031/56.

26. 20020106746. 04 Oct 01. 08 Aug 02. Anti-inflammatory vectors. Rooke, Ronald. 435/91.33; 424/199.1 424/204.1 424/233.1 424/93.21 435/235.1 435/320.1 435/456 435/91.41 530/388.7 536/23.72 A61K048/00 C12N007/00 C12N015/861 C07H021/04 C12P019/34 C12N015/64 C12N015/66 A01N063/00 A61K039/12 A61K039/23 A61K039/235 C12N007/01 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74 C07K016/00 C12P021/08 C12N015/86.

27. 20020090717. 16 Jan 02. 11 Jul 02. Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus. Gao, Guangping, et al. 435/239;

435/235.1 435/367 435/455 435/456 435/464 435/465 435/476 435/70.3 C12P021/04 C12N007/00
C12N007/01 C12N007/02 C12N005/08 C12N015/63 C12N015/85 C12N015/87 C12N015/86
C12N015/74.

28. 20010039046. 26 Jan 01. 08 Nov 01. Viable contaminant particle free adenoviruses, their preparation and use. Yeh, Patrice, et al. 435/320.1; 435/235.1 C12N007/01 C12N015/33.

29. 20010016192. 28 Oct 97. 23 Aug 01. RECOMBINANT ADENOVIRAL VECTOR AND METHOD OF USE. GREGORY, RICHARD J., et al. 424/93.2; 424/93.6 435/320.1 435/455 435/456 435/69.1 A61K048/00 C12N015/861.

30. 20010006946. 08 Jul 98. 05 Jul 01. COMPOSITIONS AND METHODS FOR ENHANCING DELIVERY OF THERAPEUTIC AGENTS TO CELLS. ENGLER, HEIDRUN, et al. 514/44; 424/93.1 A61K048/00.

31. 20010006629. 24 Nov 99. 05 Jul 01. RECOMBINANT ADENOVIRAL VECTOR AND METHODS OF USE. GREGORY, RICHARD J., et al. 424/93.1; 424/93.2 424/93.6 435/320.1 514/44 A61K048/00 C12N015/861.

32. 6764674. 27 Dec 99; 20 Jul 04. Adenovirus E1B shuttle vectors. Hermiston; Terry, et al. 424/93.2; 435/235.1 435/320.1 435/325 435/358 435/365 435/367 435/455 435/456 435/471. A01N063/00 A61K048/00.

33. 6753321. 14 Sep 01; 22 Jun 04. Method of modulating neovascularization. Kovesdi; Imre. 514/44; 424/93.2 435/320.1 435/455 435/456. A61K048/00.

34. 6692956. 04 Oct 01; 17 Feb 04. Recombinant adenoviral vectors. Rooke; Ronald. 435/320.1; 424/233.1. C12N015/63 C12N015/00.

35. 6682929. 23 Jul 01; 27 Jan 04. Adenovector complementing cells. Brough; Douglas E., et al. 435/371; 435/320.1 435/325 435/366. C12N005/10 C12N015/861.

36. 6677156. 23 Jul 01; 13 Jan 04. Non-adenoviral gene product-based complementing cells for adenoviral vectors. Brough; Douglas E., et al. 435/456; 435/320.1 435/325 435/366 435/367 435/368 435/369 435/370 435/371 435/372 435/372.1 435/372.2 435/373 435/455 435/457. C12N005/10 C12N015/63 C12N015/861.

37. 6482617. 26 Jan 01; 19 Nov 02. Viable contaminant particle free adenoviruses, their preparation and use. Yeh; Patrice, et al. 435/91.4; 424/93.2 435/320.1 435/455 435/456 435/91.1 435/91.41 435/91.42. C12N015/64 C12N015/861 A61K048/00.

38. 6475480. 06 Jul 99; 05 Nov 02. Use of adenoviral E4 reading frames to improve expression of a gene of interest. Mehtali; Majid, et al. 424/93.2; 435/235.1 435/320.1 435/440 435/455 435/456 514/44. A01N063/00 A01N043/04 C12N015/00 C12N007/00 C12N015/63.

39. 6410298. 11 Sep 00; 25 Jun 02. Adenovirus vectors and method for reducing homologous recombination phenomena. Crouzet; Joel, et al. 435/235.1; 435/325 435/5 435/6 435/69.1 536/23.1. C12N007/00 C12Q001/70 C12Q001/68 C12P021/06 C07H021/02.

40. 6392069. 08 Jul 98; 21 May 02. Compositions for enhancing delivery of nucleic acids to cells. Engler; Heidrun, et al. 552/509; 536/5. C07J053/00.

41. 6365394. 11 Sep 00; 02 Apr 02. Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus. Gao; Guangping, et al. 435/239; 435/235.1 435/367 435/455 435/456 435/464 435/465 435/476 435/70.3. C12N007/00 C12N015/64 C12N007/02 C12P001/00.

42. 6312946. 22 Apr 97; 06 Nov 01. Viable contaminant particle free adenoviruses, their preparation and use. Yeh; Patrice, et al. 435/320.1; 424/93.2 424/93.21 435/455 435/456 514/44. C12N015/861 A61K048/00.

43. 6210939. 25 Oct 94; 03 Apr 01. Recombinant adenoviral vector and methods of use. Gregory; Richard J., et al. 435/456; 435/252.3 435/320.1 435/363 435/366 435/370 435/371. C12N005/10 C12N015/10 C12N015/63 C12N015/86.

44. 6165779. 07 Jan 97; 26 Dec 00. Compositions and methods for therapeutic use. Engler; Heidrun, et al. 435/320.1; 424/199.1 435/235.1 514/44. C12N015/63 C12N007/00 A61K038/00 A61K048/00.

45. 5981275. 14 Apr 97; 09 Nov 99. Transgene expression system for increased persistence. Armentano; Donna, et al. 435/320.1.; C12N015/00.

46. 5962429. 22 Nov 96; 05 Oct 99. Complexes of adenovirus with cationic molecules. Welsh; Michael J., et al. 514/44; 424/93.2 424/93.6 435/455 435/456. A61K048/00.

47. 5932210. 28 Oct 97; 03 Aug 99. Recombinant adenoviral vector and methods of use. Gregory; Richard J., et al. 424/93.2; 424/93.6 435/320.1. A61K048/00 C12N015/86.

Terms	Documents
L2 and (tumor near suppressor\$ or p53 or p21 or WT1 or p16 or mitosin or Rb)	47

[Prev Page](#) [Next Page](#) [Go to Doc#](#)

 PALM INTRANETDay : Tuesday
Date: 8/24/2004

Time: 13:37:02

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

 **PALM INTRANET**Day : Tuesday
Date: 8/24/2004

Time: 13:37:02

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

 PALM INTRANET

Day : Tuesday
Date: 8/24/2004

Time: 13:37:02

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name First Name

manevel	daniel c	Search
---------	----------	--------

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)